Akoya Biosciences Inc expected to post a loss of 27 cents a share - Earnings Preview

Akoya Biosciences

01/03/2024 21:30

* Akoya Biosciences Inc  AKYA.OQ   AKYA.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 4
for the period ending December 31 2023
    * The Marlborough Massachusetts-based  company is expected
to
report a 22.0% increase in revenue to $25.89 million from $21.22
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.The company's guidance on January 7
2024, for the period ended December 31, was for revenue between
$25.50 million and $26.50 million.
    * ​LSEG's mean analyst estimate for Akoya Biosciences Inc is
for a
loss of 27 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Akoya
Biosciences
Inc is $8.50​, above​ its last closing price of $5.74. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.36       -0.37      -0.26     Beat    28.9
 Jun. 30 2023  -0.43       -0.44      -0.46     Missed  -3.9
 Mar. 31 2023  -0.50       -0.48      -0.49     Missed  -1.5​
 Dec. 31 2022  -0.44       -0.43      -0.50     Missed  -16.3
 ​​Sep.        -0.49       -0.44      -0.47     Missed  -6.8
 30 2022                                                
 Jun. 30 2022  -0.39       -0.37      -0.47     Missed  -26.3​
 Mar. 31 2022  -0.40       -0.39      -0.44     Missed  -13.5
 Dec. 31 2021  -0.29       -0.31      -0.47     Missed  -51.6
 This summary was machine generated March 1 at 21:30 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)